Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis

[1]  B. Davis,et al.  Effect of antihypertensive drug treatment on long-term blood pressure reduction: An individual patient-level data meta-analysis of 352,744 Participants from 51 large-scale randomised clinical trials , 2021, medRxiv.

[2]  K. Rahimi,et al.  Limitations of subgroup analysis of underpowered clinical trials for making causal inference about treatment effects. , 2020, European heart journal.

[3]  Natalie S Blencowe,et al.  RoB 2: a revised tool for assessing risk of bias in randomised trials , 2019, BMJ.

[4]  K. Bhaskaran,et al.  Eligibility and subsequent burden of cardiovascular disease of four strategies for blood pressure-lowering treatment: a retrospective cohort study , 2019, The Lancet.

[5]  K. Rahimi,et al.  Systolic Blood Pressure and Risk of Valvular Heart Disease: A Mendelian Randomization Study. , 2019, JAMA cardiology.

[6]  Kazem Rahimi,et al.  BEHRT: Transformer for Electronic Health Records , 2019, Scientific Reports.

[7]  K. Rahimi,et al.  Long‐Term Exposure to Elevated Systolic Blood Pressure in Predicting Incident Cardiovascular Disease: Evidence From Large‐Scale Routine Electronic Health Records , 2019, Journal of the American Heart Association.

[8]  B. Davis,et al.  Investigating the stratified efficacy and safety of pharmacological blood pressure-lowering: an overall protocol for individual patient-level data meta-analyses of over 300 000 randomised participants in the new phase of the Blood Pressure Lowering Treatment Trialists’ Collaboration (BPLTTC) , 2019, BMJ Open.

[9]  Ewout Steyerberg,et al.  Personalized evidence based medicine: predictive approaches to heterogeneous treatment effects , 2018, British Medical Journal.

[10]  Corrigendum to: 2018 ESC/ESH Guidelines for the management of arterial hypertension. , 2018, European heart journal.

[11]  M. Woodward,et al.  Elevated blood pressure and risk of aortic valve disease: a cohort analysis of 5.4 million UK adults , 2018, European heart journal.

[12]  G. Lip,et al.  2018 ESC/ESH Guidelines for the management of arterial hypertension. , 2018, European heart journal.

[13]  K. Rahimi,et al.  Blood pressure-lowering treatment lowers mortality and cardiovascular disease risk, but whether effects differ at an arbitrary threshold of 140 mm Hg systolic blood pressure requires further research , 2018, BMJ Evidence-Based Medicine.

[14]  Jackson T. Wright,et al.  2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2018, Journal of the American College of Cardiology.

[15]  B. Davis,et al.  Blood pressure-lowering treatment strategies based on cardiovascular risk versus blood pressure: A meta-analysis of individual participant data , 2018, PLoS medicine.

[16]  R. Brook,et al.  2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2018, Journal of the American Society of Hypertension : JASH.

[17]  Terence Dwyer,et al.  Elevated blood pressure and risk of mitral regurgitation: A longitudinal cohort study of 5.5 million United Kingdom adults , 2017, PLoS medicine.

[18]  S. Yusuf,et al.  Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials , 2017, The Lancet.

[19]  K. Rahimi,et al.  Patients with coronary heart disease and very low blood pressure are at increased risk of cardiovascular events , 2017, Evidence-Based Medicine.

[20]  Deepak L. Bhatt,et al.  Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study , 2016, The Lancet.

[21]  Jackson T. Wright,et al.  A Randomized Trial of Intensive versus Standard Blood-Pressure Control. , 2016, The New England journal of medicine.

[22]  Mark Woodward,et al.  Usual blood pressure, atrial fibrillation and vascular risk: evidence from 4.3 million adults , 2016, International journal of epidemiology.

[23]  S. Yusuf,et al.  Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. , 2016, The New England journal of medicine.

[24]  S. Anderson,et al.  Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis , 2016, The Lancet.

[25]  S. Anderson,et al.  Usual Blood Pressure and Risk of New-Onset Diabetes , 2015, Journal of the American College of Cardiology.

[26]  Mark Woodward,et al.  Usual blood pressure, peripheral arterial disease, and vascular risk: cohort study of 4.2 million adults , 2015, BMJ : British Medical Journal.

[27]  K. Rahimi,et al.  Effect of antihypertensive agents on risk of atrial fibrillation: a meta-analysis of large-scale randomized trials. , 2015, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[28]  K. Rahimi,et al.  The epidemiology of blood pressure and its worldwide management. , 2015, Circulation research.

[29]  M. Woodward,et al.  Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis. , 2015, Annals of internal medicine.

[30]  M. Woodward,et al.  Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data , 2014, The Lancet.

[31]  K. Rahimi,et al.  Blood pressure management in the 21st century: maximizing gains and minimizing waste. , 2013, Circulation.

[32]  G. Panjrath,et al.  The J-curve between blood pressure and coronary artery disease or essential hypertension: exactly how essential? , 2009, Journal of the American College of Cardiology.

[33]  P. Williamson,et al.  A comparison of methods for fixed effects meta-analysis of individual patient data with time to event outcomes , 2007, Clinical trials.

[34]  Stephen W Lagakos,et al.  Statistics in medicine--reporting of subgroup analyses in clinical trials. , 2007, The New England journal of medicine.

[35]  Y. Kanno,et al.  Effects of Candesartan on Cardiovascular Outcomes in Japanese Hypertensive Patients , 2005, Hypertension Research.

[36]  G. Remuzzi,et al.  Preventing microalbuminuria in type 2 diabetes. , 2004, The New England journal of medicine.

[37]  M. Pepe,et al.  Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. , 2004, American journal of epidemiology.

[38]  S. Lewington.  Prospective studies collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies (vol 360, pg 1903, 2002) , 2003 .

[39]  R. Collins,et al.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002, The Lancet.

[40]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[41]  G. Hommel.  A stagewise rejective multiple test procedure based on a modified Bonferroni test , 1988 .

[42]  B. Carlberg,et al.  Association of Blood Pressure Lowering With Mortality and Cardiovascular Disease Across Blood Pressure Levels: A Systematic Review and Meta-analysis , 2018, JAMA internal medicine.

[43]  C. Escobar Cervantes,et al.  [A randomized trial of intensive versus standard blood pressure control]. , 2016, Semergen.